This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension

This study has been completed.
Sponsor:
Information provided by:
Alcon Research
ClinicalTrials.gov Identifier:
NCT00576251
First received: December 17, 2007
Last updated: February 23, 2010
Last verified: February 2010
December 17, 2007
February 23, 2010
October 2007
February 2008   (Final data collection date for primary outcome measure)
Percent of Patients Who Display Microbiological Success (Eradication of Baseline Pathogens at Day 4) [ Time Frame: Day 4 - Test Of Cure (TOC) compared to Day 0 ]
Microbiological success was declared if the pre-therapy pathogens were eradicated at the Exit Visit; conversely, microbiological failure was declared if pre-therapy pathogens persisted at the exit visit. The microbiological outcomes were calculated based on an algorithm that assessed whether pre-therapy pathogens were eradicated or persisted as demonstrated by comparative characterization of recovered bacteria.
Ocular inflammation at Visits 2-5 [ Time Frame: 2 -5 weeks ]
Complete list of historical versions of study NCT00576251 on ClinicalTrials.gov Archive Site
Not Provided
Microbiologiocal [ Time Frame: Week 5 ]
Not Provided
Not Provided
 
TOBRADEX Ophthalmic Suspension Versus Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension
Not Provided
The purpose of this study is to describe the differences in efficacy between TOBRADEX Ophthalmic Suspension and Tobramycin 0.3%/Dexamethasone 0.05% Ophthalmic Suspension in the treatment of ocular inflammation and infection associated with blepharaconjunctivitis
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Ocular Inflammation Associated With Blepharaconjunctivitis
  • Drug: Tobramycin 0.3%/Dexamethasone 0.05%
    Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
  • Drug: TOBRADEX
    TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
  • Experimental: Tobramycin 0.3%/Dexamethasone 0.05%
    Tobramycin 0.3%/Dexamethasone 0.05% 1 drop 4 times daily in both eyes
    Intervention: Drug: Tobramycin 0.3%/Dexamethasone 0.05%
  • Active Comparator: TOBRADEX
    TOBRADEX 1 drop 4 times daily in both eyes
    Intervention: Drug: TOBRADEX
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
221
March 2008
February 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ocular inflammation associated with blepharaconjunctivitis

Exclusion Criteria:

  • ocular allergy
  • ocular disorders that would preclude safe administration of test article
Sexes Eligible for Study: All
2 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00576251
C-07-19
No
Not Provided
Not Provided
Judy Vittitoe, Alcon Research
Alcon Research
Not Provided
Study Director: Michael Brubaker, BSN MPH Alcon Research
Alcon Research
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP